Press Releases

2015

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

Selecta Biosciences 12.23.2015

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Agios Pharmaceuticals 12.18.2015

BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer

BIND Therapeutics 12.16.2015

Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors

Moderna 12.15.2015

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics 12.14.2015

BIND Therapeutics to Advance BIND-014 Squamous Histology Non-Small Cell Lung Cancer Cohort to Second Stage of iNSITE 1 Trial

BIND Therapeutics 12.14.2015

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes

Acceleron Pharma 12.11.2015

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Acceleron Pharma 12.11.2015

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

Agios Pharmaceuticals 12.11.2015

EcoSense Lighting Acquires Journee Lighting

Korrus 12.11.2015

Loading